PDCD1 and non-small cell lung carcinoma: Recently, designed programmed cell death-1 (PD-1) blocking antibodies have been found to produce excellent effects concerning the medication of numerous tumors, containing melanoma, non-small-cell lung cell cancer, and bladder cancer (1–3).